AR072639A1 - Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropina - Google Patents

Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropina

Info

Publication number
AR072639A1
AR072639A1 ARP090102928A ARP090102928A AR072639A1 AR 072639 A1 AR072639 A1 AR 072639A1 AR P090102928 A ARP090102928 A AR P090102928A AR P090102928 A ARP090102928 A AR P090102928A AR 072639 A1 AR072639 A1 AR 072639A1
Authority
AR
Argentina
Prior art keywords
pirazinonas
modulators
compound
releasing factor
receiver activity
Prior art date
Application number
ARP090102928A
Other languages
English (en)
Spanish (es)
Inventor
Vijay T Ahuja
Vivekananda Y Vrudhula
Joanne J Bronson
Richard A Hartz
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR072639A1 publication Critical patent/AR072639A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP090102928A 2008-07-31 2009-07-30 Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropina AR072639A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8523008P 2008-07-31 2008-07-31

Publications (1)

Publication Number Publication Date
AR072639A1 true AR072639A1 (es) 2010-09-08

Family

ID=40651774

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102928A AR072639A1 (es) 2008-07-31 2009-07-30 Pirazinonas como moduladores de la actividad del receptor del factor liberador de corticotropina

Country Status (10)

Country Link
US (2) US7932256B2 (cg-RX-API-DMAC7.html)
EP (1) EP2303867B1 (cg-RX-API-DMAC7.html)
JP (1) JP5396474B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110040870A (cg-RX-API-DMAC7.html)
CN (1) CN102171205B (cg-RX-API-DMAC7.html)
AR (1) AR072639A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009277057A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011000754A (cg-RX-API-DMAC7.html)
TW (1) TW201008926A (cg-RX-API-DMAC7.html)
WO (1) WO2010014280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
KR20210064407A (ko) 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
IT201900021216A1 (it) 2019-11-14 2021-05-14 Isagro Spa Processo per la preparazione di derivati piridinici e corrispondenti piridil-formammidine
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
CN112552184B (zh) * 2020-12-18 2022-05-10 诚达药业股份有限公司 一种含环丙基手性胺盐酸盐的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine
HRP20031096A2 (en) * 2001-06-12 2005-08-31 Neurogen Corporation 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
AU2003278542A1 (en) 2002-11-21 2004-06-15 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators

Also Published As

Publication number Publication date
TW201008926A (en) 2010-03-01
WO2010014280A1 (en) 2010-02-04
EP2303867B1 (en) 2014-12-17
MX2011000754A (es) 2011-02-24
US8372847B2 (en) 2013-02-12
JP2011529886A (ja) 2011-12-15
CN102171205B (zh) 2013-08-07
US20110166160A1 (en) 2011-07-07
US7932256B2 (en) 2011-04-26
JP5396474B2 (ja) 2014-01-22
AU2009277057A1 (en) 2010-02-04
CN102171205A (zh) 2011-08-31
US20100029684A1 (en) 2010-02-04
KR20110040870A (ko) 2011-04-20
EP2303867A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
MX382599B (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina.
DOP2013000267A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3
UY30253A1 (es) Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
ME01532B (me) Jedinjenja
UY32966A (es) Octahidropirrolo (3,4-c) pirroles disustituidos como moduladores del receptor de orexina
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
MX358640B (es) Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
BRPI0910368B8 (pt) uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
CL2012000185A1 (es) Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer.
IN2012DN02469A (cg-RX-API-DMAC7.html)
CU23874B1 (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
CL2007001731A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal